Neurologists and other healthcare professionals interested in the diagnosis and management of patients who may progress to have Alzheimer’s disease
Estimated time to complete the program: 0.5 hour
Alzheimer's Disease: Utilization of Novel Diagnostic Tools and a Better Understanding of Emerging Pharmacotherapies
In the US, 5.4 million people suffer from Alzheimer's disease (AD). Roughly 96% of these people are 65 or older, and the prevalence of AD in this group is expected to increase 30% by 2025. AD was responsible for 82,435 deaths in 2008 and is currently considered the 6th leading cause of death in the US. Though much research has been done to better understand the pathophysiology process of AD and to develop effective, targeted treatments for this disease, there are currently no treatment options available to halt or reverse the progression of AD. Diagnostic tools have been and are being developed in order to detect AD progression at an earlier stage, but there is a clear underutilization of these novel diagnostic tools and technologies. There is some evidence to indicate that earlier treatment with currently available therapies may delay the progression of AD, although no significant reduction in long-term risk has been observed. Nevertheless, the observed delay in progression highlights the potential impact of effective early diagnosis and management of AD on the quality of life of patients. Thus, there is a clear need to educate clinicians on when to use these novel diagnostic methods and who the appropriate patients may be so that AD can be diagnosed at an early stage. This case-based activity is designed to educate neurologists and will focus on a patient with mild cognitive impairment and the most effective diagnostic methods for early determination of progression of AD. Furthermore, safety, efficacy, and clinical trial data regarding the current and emerging pharmacotherapies for the treatment of AD will be discussed.
This activity is designed for neurologists and other healthcare professionals who may be interested in the diagnosis and management of patients who may progress to have Alzheimer's disease.
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Elsevier Office of Continuing Medical Education and ACCELMED. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education (EOCME) that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
James B. Brewer, MD, PhD
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 18.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 13.0+ for Windows, Mac OS, or Linux
Safari 4.0+ for Mac OSX 10.5 and above
|Supported Phones & Tablets:|
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above